Curtiss-Wright Corp has a consensus price target of $259.67 based on the ratings of 7 analysts. The high is $330 issued by Morgan Stanley on May 23, 2024. The low is $170 issued by Wolfe Research on October 11, 2022. The 3 most-recent analyst ratings were released by Stifel, Morgan Stanley, and Truist Securities on July 18, 2024, May 23, 2024, and May 22, 2024, respectively. With an average price target of $306 between Stifel, Morgan Stanley, and Truist Securities, there's an implied 8.77% upside for Curtiss-Wright Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/18/2024 | Buy Now | 13.03% | Stifel | Nathan Jones | $310 → $318 | Maintains | Buy | Get Alert |
05/23/2024 | Buy Now | 17.3% | Morgan Stanley | Kristine Liwag | $284 → $330 | Maintains | Overweight | Get Alert |
05/22/2024 | Buy Now | -4.03% | Truist Securities | Michael Ciarmoli | $252 → $270 | Maintains | Hold | Get Alert |
05/22/2024 | Buy Now | 10.19% | Stifel | Nathan Jones | $293 → $310 | Maintains | Buy | Get Alert |
05/03/2024 | Buy Now | 4.14% | Stifel | Nathan Jones | $272 → $293 | Maintains | Buy | Get Alert |
05/03/2024 | Buy Now | 0.95% | Morgan Stanley | Kristine Liwag | $260 → $284 | Maintains | Overweight | Get Alert |
05/03/2024 | Buy Now | -10.43% | Truist Securities | Michael Ciarmoli | $240 → $252 | Maintains | Hold | Get Alert |
04/17/2024 | Buy Now | -3.32% | Stifel | Nathan Jones | $255 → $272 | Maintains | Buy | Get Alert |
04/08/2024 | Buy Now | 6.63% | Baird | Peter Arment | $246 → $300 | Maintains | Outperform | Get Alert |
03/25/2024 | Buy Now | -14.69% | Truist Securities | Michael Ciarmoli | → $240 | Downgrade | Buy → Hold | Get Alert |
02/16/2024 | Buy Now | -9.36% | Stifel | Nathan Jones | $244 → $255 | Maintains | Buy | Get Alert |
01/23/2024 | Buy Now | -13.27% | Stifel | Nathan Jones | $243 → $244 | Maintains | Buy | Get Alert |
12/14/2023 | Buy Now | -11.14% | Truist Securities | Michael Ciarmoli | $225 → $250 | Maintains | Buy | Get Alert |
11/29/2023 | Buy Now | -13.63% | Stifel | Nathan Jones | $227 → $243 | Maintains | Buy | Get Alert |
11/03/2023 | Buy Now | -20.03% | Truist Securities | Michael Ciarmoli | $215 → $225 | Maintains | Buy | Get Alert |
10/20/2023 | Buy Now | -23.58% | Truist Securities | Michael Ciarmoli | → $215 | Reiterates | Buy → Buy | Get Alert |
08/07/2023 | Buy Now | -18.6% | Morgan Stanley | Kristine Liwag | $188 → $229 | Upgrade | Equal-Weight → Overweight | Get Alert |
08/04/2023 | Buy Now | -18.96% | Baird | Peter Arment | $200 → $228 | Maintains | Outperform | Get Alert |
07/21/2023 | Buy Now | -25% | Truist Securities | Michael Ciarmoli | $190 → $211 | Maintains | Buy | Get Alert |
07/19/2023 | Buy Now | -27.49% | Stifel | Nathan Jones | $200 → $204 | Maintains | Buy | Get Alert |
05/19/2023 | Buy Now | — | William Blair | Louie DiPalma | — | Reinstates | → Outperform | Get Alert |
04/17/2023 | Buy Now | -28.91% | Stifel | Nathan Jones | $196 → $200 | Maintains | Buy | Get Alert |
02/23/2023 | Buy Now | -32.47% | Truist Securities | Michael Ciarmoli | $183 → $190 | Maintains | Buy | Get Alert |
12/12/2022 | Buy Now | -33.18% | Morgan Stanley | Kristine Liwag | $187 → $188 | Downgrade | Overweight → Equal-Weight | Get Alert |
11/07/2022 | Buy Now | -33.53% | Morgan Stanley | Kristine Liwag | $180 → $187 | Maintains | Overweight | Get Alert |
10/11/2022 | Buy Now | -41.35% | Stifel | Nathan Jones | $162 → $165 | Maintains | Buy | Get Alert |
10/11/2022 | Buy Now | -39.57% | Wolfe Research | Myles Walton | → $170 | Initiates | → Outperform | Get Alert |
07/19/2022 | Buy Now | -41% | Truist Securities | Michael Ciarmoli | $167 → $166 | Maintains | Buy | Get Alert |
07/18/2022 | Buy Now | -44.91% | Stifel | Nathan Jones | $168 → $155 | Maintains | Buy | Get Alert |
03/01/2022 | Buy Now | -32.82% | Morgan Stanley | Kristine Liwag | $180 → $189 | Maintains | Overweight | Get Alert |
01/21/2022 | Buy Now | -39.57% | Berenberg | Christopher Rieger | → $170 | Initiates | → Buy | Get Alert |
12/03/2021 | Buy Now | -36.02% | Morgan Stanley | Kristine Liwag | — | Initiates | → Overweight | Get Alert |
09/29/2021 | Buy Now | -44.2% | Baird | Peter Arment | — | Upgrade | Neutral → Outperform | Get Alert |
The latest price target for Curtiss-Wright (NYSE:CW) was reported by Stifel on July 18, 2024. The analyst firm set a price target for $318.00 expecting CW to rise to within 12 months (a possible 13.03% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Curtiss-Wright (NYSE:CW) was provided by Stifel, and Curtiss-Wright maintained their buy rating.
The last upgrade for Curtiss-Wright Corp happened on August 7, 2023 when Morgan Stanley raised their price target to $229. Morgan Stanley previously had an equal-weight for Curtiss-Wright Corp.
The last downgrade for Curtiss-Wright Corp happened on March 25, 2024 when Truist Securities changed their price target from $250 to $240 for Curtiss-Wright Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Curtiss-Wright, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Curtiss-Wright was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
While ratings are subjective and will change, the latest Curtiss-Wright (CW) rating was a maintained with a price target of $310.00 to $318.00. The current price Curtiss-Wright (CW) is trading at is $281.34, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.